Cargando…

Interferon Beta-1a versus Glatiramer Acetate: Changes of Innate Immunity in a Group of Women with Multiple Sclerosis

INTRODUCTION: Multiple sclerosis (MS) is a chronic inflammatory autoimmune demyelinating disease that secondarily leads to axonal loss and associated brain atrophy. Disease-modifying drugs (DMDs) have previously been studied for their ability to affect specific immunity. This study investigates the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peterka, Marek, Valis, Martin, Soucek, Ondrej, Krejsek, Jan, Sobisek, Lukáš, Sejkorova, Ilona, Klimova, Blanka, Stourac, Pavel, Pavelek, Zbysek, Novotny, Michal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2023
Materias:	Basic Investigative Studies: Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623392/ https://www.ncbi.nlm.nih.gov/pubmed/37473734 http://dx.doi.org/10.1159/000532022

Ejemplares similares

Assessment of Functional Capacity of Immune System in Patients with Multiple Sclerosis using QuantiFERON Monitor
por: Pavelek, Zbysek, et al.
Publicado: (2023)

CD4+/CD45RO+: A Potential Biomarker of the Clinical Response to Glatiramer Acetate
por: Vališ, Martin, et al.
Publicado: (2019)

The role of the immune system and the biomarker CD3 + CD4 + CD45RA−CD62L− in the pathophysiology of migraine
por: Pavelek, Zbyšek, et al.
Publicado: (2020)

Innate Immune System and Multiple Sclerosis. Granulocyte Numbers Are Reduced in Patients Affected by Relapsing-Remitting Multiple Sclerosis during the Remission Phase
por: Pavelek, Zbyšek, et al.
Publicado: (2020)

Highly active RRMS and ocrelizumab after failure of alemtuzumab therapy
por: Vališ, Martin, et al.
Publicado: (2020)

Analysis of the Group of Pediatric Patients With Relapsing-Remitting Multiple Sclerosis: Data From the Czech National Registry
por: Vališ, Martin, et al.
Publicado: (2022)

Treatment of behavioral and psychological symptoms of dementias with psychopharmaceuticals: a review
por: Masopust, Jiří, et al.
Publicado: (2018)

Comparison of Therapies in MS Patients After the First Demyelinating Event in Real Clinical Practice in the Czech Republic: Data From the National Registry ReMuS
por: Pavelek, Zbyšek, et al.
Publicado: (2021)

Proteomic analysis of cerebrospinal fluid for relapsing-remitting multiple sclerosis and clinically isolated syndrome
por: PAVELEK, ZBYŠEK, et al.
Publicado: (2016)

The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis
por: Vališ, Martin, et al.
Publicado: (2023)

Follow-on glatiramer acetate
por: Cohen, Jeffrey A., et al.
Publicado: (2018)

Glatiramer acetate treatment negatively regulates type I interferon signaling
Publicado: (2015)

Glatiramer acetate treatment negatively regulates type I interferon signaling
por: Molnarfi, Nicolas, et al.
Publicado: (2015)

The Concentration of Memantine in the Cerebrospinal Fluid of Alzheimer’s Disease Patients and Its Consequence to Oxidative Stress Biomarkers
por: Valis, Martin, et al.
Publicado: (2019)

Tourette Syndrome: A Mini-Review
por: Novotny, Michal, et al.
Publicado: (2018)

Nitrendipine and Dementia: Forgotten Positive Facts?
por: Novotny, Michal, et al.
Publicado: (2018)

PPI Long Term Use: Risk of Neurological Adverse Events?
por: Novotny, Michal, et al.
Publicado: (2019)

Microbiome and Cognitive Impairment: Can Any Diets Influence Learning Processes in a Positive Way?
por: Novotný, Michal, et al.
Publicado: (2019)

The Impact of Nutrition and Intestinal Microbiome on Elderly Depression—A Systematic Review
por: Klimova, Blanka, et al.
Publicado: (2020)

Glatiramer acetate in the treatment of multiple sclerosis
por: Tselis, Alex, et al.
Publicado: (2007)

Differential Transcription of SOCS5 and SOCS7 in Multiple Sclerosis Patients Treated with Interferon Beta or Glatiramer Acetate
por: Rojas-Morales, Emmanuel, et al.
Publicado: (2019)

The effectiveness of interferon beta versus glatiramer acetate and natalizumab versus fingolimod in a Polish real-world population
por: Kapica-Topczewska, Katarzyna, et al.
Publicado: (2019)

Effect Of An Extra-Virgin Olive Oil Intake On The Delay Of Cognitive Decline: Role Of Secoiridoid Oleuropein?
por: Klimova, Blanka, et al.
Publicado: (2019)

Antiplatelet Therapy in the Secondary Prevention of Non-cardioembolic Ischemic Stroke and Transient Ischemic Attack: A Mini-Review
por: Vališ, Martin, et al.
Publicado: (2021)

The Effect of Mediterranean Diet on Cognitive Functions in the Elderly Population
por: Klimova, Blanka, et al.
Publicado: (2021)

Flare Up Reaction During Provocation Test to Glatiramer Acetate in a Patient With Allergy to Interferon Beta1a
por: Minciullo, Paola L., et al.
Publicado: (2014)

B-Cell Activity Predicts Response to Glatiramer Acetate and Interferon in Relapsing-Remitting Multiple Sclerosis
por: Tacke, Sabine, et al.
Publicado: (2021)

Demonstration of Equivalence of Generic Glatiramer Acetate and Copaxone(®)
por: Lipsky, Peter, et al.
Publicado: (2021)

Acupuncture in migraine prophylaxis in Czech patients: an open-label randomized controlled trial
por: Musil, Frantisek, et al.
Publicado: (2018)

Differential glatiramer acetate treatment persistence in treatment-naive patients compared to patients previously treated with interferon
por: Fernández-Fournier, Mireya, et al.
Publicado: (2015)

Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC score
por: Bsteh, Gabriel, et al.
Publicado: (2021)

The role of glatiramer acetate in the early treatment of multiple sclerosis
por: Brandes, David W
Publicado: (2010)

Spasticity in multiple sclerosis and role of glatiramer acetate treatment
por: Meca-Lallana, Jose Eustasio, et al.
Publicado: (2015)

Glatiramer Acetate-associated Refractory Immune Thrombocytopenic Purpura
por: Sagy, Iftach, et al.
Publicado: (2016)

Physicochemical and Biological Examination of Two Glatiramer Acetate Products
por: Komlosh, Arthur, et al.
Publicado: (2019)

Bullous pemphigoid as an injection site reaction of glatiramer acetate
por: Baghbanian, Seyed Mohammad, et al.
Publicado: (2019)

Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation
por: Kasindi, Arielle, et al.
Publicado: (2022)

An Immunomodulatory Peptide Dendrimer Inspired from Glatiramer Acetate
por: Erzina, Dina, et al.
Publicado: (2021)

Manifestation of Susac syndrome during interferon beta-1a and glatiramer acetate treatment for misdiagnosed multiple sclerosis: a case report
por: Roskal-Wałek, Joanna, et al.
Publicado: (2021)

Adverse side effects of Glatiramer acetate and Interferon beta-1a in patients with multiple sclerosis: A systematic review of case reports
por: Rastkar, Mohsen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hv2r9grcvromlbkgsmjmgr6hh2